DENISE KEENE: Open Payments
NPI 1457830770 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,590 in 92 payments from 10 companies in 2025. Trend: 2023 $1,088 · 2024 $389 · 2025 $1,590
Food & beverage: $1,359Education: $231
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 31 | $546 |
| E.R. Squibb & Sons, L.L.C. | 33 | $401 |
| Neurocrine BioSciences, Inc. | 5 | $156 |
| Vanda Pharmaceuticals Inc. | 7 | $152 |
| Janssen Pharmaceuticals, Inc | 4 | $93 |
| Alkermes, Inc. | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| ABBVIE INC. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
Products named: COBENFY, UZEDY, INGREZZA, FANAPT, AUSTEDO XR, INVEGA SUSTENNA, ARISTADA, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
